Sunday, November 22nd, 2009

Posts Tagged ‘ DCGN ’

Why Standard Flu Vaccines Won’t Make Investors Rich

May 5th, 2009 | By Patrick Cox | Category: Stock Market Investing

A more recent addition to my transformational technologies portfolio, Medarex (NASDAQ:MEDX), has scored a huge win. The company, along with Massachusetts Biologic Laboratory, will get $60 million upfront from Merck (NYSE:MRK) for license rights to a monoclonal antibody that apparently cures C. difficile infection. They are eligible for another $165 million in milestones as well as royalties.